ANR 2021: 25 January 2021
16:05 - 17:05 Major Symposium 1: Progress in treatment and challenges for preclinical studies
This session will provide an update on the major treatment studies for high risk neuroblastoma and is intended for both clinical and basic researchers. This session should define the major questions in treatment of neuroblastoma, both from a basic and clinical point of view. Relapse treatment studies will be reviewed, as well as local tumor control by surgery and radiotherapy and the role of new imaging technologies.
17.10- 18.25 Major Symposium 2: Neuroblastoma as a developmental disorder
Neuroblastoma is marked by inter-tumor heterogeneity defining stages with highly divergent outcomes, but also by intra-tumour heterogeneity which may underlie relapse development. New technologies currently redefine the normal development of the sympatho-adrenergic lineage. This session will integrate the latest insights in normal development, tumor heterogeneity and clinical behaviour.
18:30 - 19:30 Parallel sessions
PA1: Treatment relapse Neuroblastoma
PA2: Omics, new concepts
PA3: Neuroblastoma as development disorder
PA4: Clinical – Neuroblastoma frontline therapy
End of day 1
ANR2021: Tuesday 26 January 2021
16:00-17.00 Major Symposium 3: A deep look into neuroblastoma
Single cell analysis is revolutionizing cancer research. The results for neuroblastoma will be presented in this session, offering insight in intra-tumor heterogeneity, immune and stromal infiltrate and clinical consequences.
17.10-18.15 Major Symposium 4: Neuroblastoma tumour biology and genomics: from bench to the clinic
This session will focus on insights from novel layers of omics information of gene mutations, structural defects and other high throughput data. It will address the relation between these defects and relapse potential and clinical development, as well as functional studies of these defects. Potential drug targets and new bioinformatic tools to study them will be addressed.
18.20 - 19.20 Parallel sessions
PA5: Heterogeneity in Neuroblastoma
PA7: Liquid biopsies
PA8: Immune therapy
End of day 2
ANR2021: Wednesday 27 January 2021
21.00-22.05 Major Symposium 5: Targeted therapy: ALK and other targets in personalized medicine
ALK inhibition is quintessential for the development of precision medicine in neuroblastoma: early development, unclear early clinical results followed by more effective strategies and the associated challenge of resistance. Many other targets are piloted from bench to bedside and will be discussed.
22.10-23.15 Parallel Major Symposium
Major symposium 6 (Parallel with MS7 !): Gene regulatory networks and epigenetics: from basic science towards novel therapeutic strategies
Epigenetic networks are being clarified in neuroblastoma. They are linked to drug resistance and transcription factor networks that control neuroblastoma. This session will highlight these developments and the therapeutic potential of drugs interfering with epigenetics.
Major Symposium 7 (Parallel with MS6 !): Immune therapy of neuroblastoma
This session will present successes and challenges of immune therapy in neuroblastoma including updates on anti-GD2 protocols and pilot studies. The session will include studies for other targets of antibody-mediated therapy and CART approaches that are being developed and in early clinical trials.
23.20-24.20 Parallel sessions PA9 - PA13
PA9: Genomics: new genes and concepts
PA10: Targeted therapy: ALK resistance and new strategies
PA11 Core Regulatory Circuitries
PA12: Immune landscape of neuroblastoma
PA13: Hot and cold tumours
End of day 3